ArticleScientific reports2025
Unravelling anti-cancer properties of solanaceous extracts using GC-MS and HPLC.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Cancer is a complex health issue that today's medical science is dealing with, which has a mortality rate that is almost identical to that of cardiac disorders. Because of the adverse effects of the majority of the medications used in its therapy, managing it remains a major concern despite the availability of numerous remedies. This article attempts to contribute to the scientific developments in the Solanaceae family's anti-cancer field. Thus, this study consisted of isolating β-amyrin, cedryl acetate, lupeol, and 2-pentadecanone, 6,10,14-trimethyl from Cestrum aurantiacum to determine the anti-tumor activity. The plant material was dried, pulverized, and small-scale extraction was done. Brine shrimps, cell lines (A549, Hela, HEPG), and Caenorhabditis elegans were used initially to examine three solanaceous plant extracts (Solanum villosum (SV), Cestrum aurantiacum (CA), and Brugmansia suaveolens (BS)). The best results were shown by ethanol extract of Cestrum aurantiacum that why large-scale extraction and GCMS of this extract were done. The antitumor potential can be explained by the presence of β-amyrin, cedryl acetate, lupeol, and 2-pentadecanone, 6,10,14-trimethyl.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.